

Prior Authorization Criteria
Fuzeon ® (enfuvirtide)

- 1. Fuzeon will only be approved for use in children ages six and older and adults with advanced HIV infection.**
- 2. Patients must have documented failure of trials of multiple combinations of oral anti-viral therapy. This is demonstrated by the lack of appropriate response of the CD4 cell count.**
- 3. Prior approval will be given for a maximum of 24 weeks. Further documentation of the success of the enfuvirtide treatment will be necessary to continue therapy.**
- 4. Fuzeon will not be approved for monotherapy or for the initial treatment of patients with an HIV diagnosis.**
- 5. Doses of more than 90 mg. (ml.) twice daily will not be approved. In pediatric patients, doses of more than 2 mg/kg will not be approved.**
- 6. Requests for exceptions to this criteria will be considered on a case-by-case basis.**